Showing results (701-710 of 727) with videos related to
Sort By:
Pageof 73
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.Science Translational Medicine|April 5, 2013
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cellsEmre Ozkumur, Ajay M Shah, Jordan C Ciciliano, et al.NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.Antimicrobial Agents and Chemotherapy|October 13, 2020
Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action ElucidationChristoph H R Senges, Jennifer J Stepanek, Michaela Wenzel, et al.Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.Pageof 73